Biotech Values

[north40000]

WSJ take on MRK SEC filing Tuesday:

>>Johnson & Johnson is seeking damages from Merck & Co. on top of its effort to dissolve a partnership for the anti-inflammatory drugs Remicade and Simponi, Merck disclosed Tuesday.

Merck also said in a regulatory filing a loss in the case would have a "material adverse effect" on its financial position, liquidity and operational results. The company has previously played down the impact of a potential loss, saying its projection of long-term earnings growth would remain the same regardless of the outcome of the dispute. <<